Shanghai Fosun Pharmaceutical (02196) plans to sell 55% stake in Shanghai Rehab.

Shanghai Fosun Pharmaceutical (02196) announced that on April 11, 2025, the company entered into a share transfer agreement with Fosun Hi-Tech, Ms. Li Fan, and Ms. Guan Xiaohui. The company intends to sell 29.00%, 25.90%, and 0.10% of the equity in Shanghai Furen to Fosun Hi-Tech, Ms. Li Fan, and Ms. Guan Xiaohui respectively, for approximately RMB 13.9937 million, RMB 12.4978 million, and RMB 0.0483 million. The announcement stated that the business scope of Shanghai Furen includes equity investment management, investment management, and investment consulting. After this transfer is completed, the company's shareholding in Shanghai Furen will decrease from 100% before the transfer to 45%. Shanghai Furen and its holdings in Nanjing Fuxin, Xingsheng Fuying, and Shenzhen Fuxin will be converted from the company's subsidiaries to jointly operated companies. It is expected that this transfer will have no impact on the group's profit and loss. The proceeds from this transfer will be used for the group's operating funds.